代谢组学在结直肠癌早期诊断中的应用进展
Application and Progress of Metabolic Proteomics in Early Diagnosis of Colorectal Cancer
DOI: 10.12677/ACM.2016.62015, PDF, HTML, XML, 下载: 2,590  浏览: 7,576 
作者: 刘明浩, 胡文炜, 李 雪, 王瑞玲, 王瑞玲:火箭军总医院,消化内科,北京;李 萍:火箭军总医院,药剂科,北京
关键词: 结直肠癌代谢组学筛查诊断Colorectal Cancer Metabonomics Screening Diagnosis
摘要: 尽管目前结直肠癌治疗方法不断的创新与发展,其预后仍然较差,尤其是晚期结直肠癌,如病人可以早期诊断并治疗其5年生存率可以显著提高。结直肠癌不仅影响人均寿命,也对社会经济造成巨大负担。传统结直肠癌筛查方法包括便潜血检测及结肠镜检查,便潜血检测其敏感性及特异性较低;而结肠镜具有侵入性,花费较高且存在一定风险。这两项方法并不能满足结直肠癌早期诊断的要求,因此迫切需要一种筛查方法早期发现、早期诊断结直肠癌,延长结直肠癌患者生存期,改善其预后。继基因组学、转录组学、蛋白质组学之后新兴的一门“组学”称为代谢组学,其对生物体内参与生化反应成千上万中间产物及终产物进行动态的定性定量分析,可以反应生物不同生理、病理及生长状态。近期研究发现代谢组学在肿瘤的研究中具有广泛的用途,包括肿瘤早期诊断、分期、评估疗效和预测预后等,其中包括关于结直肠癌的研究,这为建立有效、稳点、可靠的结直肠癌早期诊断方法提供了新的思路。本文对代谢组学在结直肠癌中早期诊断的研究进展作一综述。
Abstract: Although the treatment methods of colorectal cancer have experienced constant innovations and development, the prognosis remains poor, especially among patients with advanced colorectal can-cer. Early diagnosis and treatment may significantly improve the five-year survival rate of these pa-tients. Colorectal cancer not only shortens mean life span, but also percolates the social economy. Traditional screening methods of colorectal cancer mainly include fecal occult blood detection and colonoscopy. Fecal occult blood detection focuses on the sensitivity of colerectal cancer but has low specificity, while colonoscopy is invasive, expensive and subject to some risk. These two methods fail to meet the requirements for early diagnosis of colorectal cancer. Therefore, there is an urgent need for a screening method for early detection and early diagnosis of colorectal cancer in order to prolong the survival time of patients with colorectal cancer and improve the prognosis. Following genomics, transcriptomics and proteomics, metabolomics comes into being as a new “omics” that carries out dynamic, quantitative and qualitative analyses of thousands of intermediate products and end products entering into a sequence of biochemical reactions, thus reflecting various physiological, pathological and growth statuses. Recent studies have found that metabolomics had a wide range of uses in cancer researches, including early tumor diagnosis, staging, therapeutic evaluation, prognosis prediction and so on; researchers on colorectal cancer also included. This provides new ways for establishing effective, stable and reliable methods of early diagnosis of colorectal cancer. This review mainly presents an introduction to the concept and research techniques of metabolomics, as well as advances in its applications in early diagnosis of colorectal cancer.
文章引用:刘明浩, 李萍, 胡文炜, 李雪, 王瑞玲, 王瑞玲. 代谢组学在结直肠癌早期诊断中的应用进展[J]. 临床医学进展, 2016, 6(2): 81-87. http://dx.doi.org/10.12677/ACM.2016.62015

参考文献

[1] Ferlay, J., Parkin, D.M. and Steliarova-Foucher, E. (2010) Estimates of Cancer Incidence and Mortality in Europe in 2008. European Journal of Cancer, 46, 765-781.
http://dx.doi.org/10.1016/j.ejca.2009.12.014
[2] Lieberman, D.A., Rex, D.K., Winawer, S.J., et al. (2012) Guidelines for Colonoscopy Surveillance after Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 143, 844-857.
http://dx.doi.org/10.1053/j.gastro.2012.06.001
[3] Hassan, C., Quintero, E., Dumonceau, J.M., et al. (2013) Post-Polypectomy Colonoscopy Surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 45, 842-851.
http://dx.doi.org/10.1055/s-0033-1344548
[4] Doubeni, C.A., Weinmann, S., Adams, K., et al. (2013) Screening Colonoscopy and Risk for Incident Late-Stage Colorectal Cancer Diagnosis in Average-Risk Adults: A Nested Case-Control Study. Annals of Internal Medicine, 158, 312-320.
http://dx.doi.org/10.7326/0003-4819-158-5-201303050-00003
[5] Imperiale, T.F. (2012) Noninvasive Screening Tests for Colorectal Cancer. Digestive Diseases, 30, 16-26.
http://dx.doi.org/10.1159/000341884
[6] Burt, R.W., Barthel, J.S., Dunn, K.B., et al. (2010) NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Journal of the National Comprehensive Cancer Network, 8, 8-61.
[7] Rochfort, S. (2005) Metabolomics Reviewed: A New “Omics” Platform Technology for Systems Biology and Implications for Natural Products Research. Journal of Natural Products, 68, 1813-1820.
http://dx.doi.org/10.1021/np050255w
[8] Saito, K. (2013) Phytochemical Genomics—A New Trend. Current Opinion in Plant Biology, 16, 373-380.
http://dx.doi.org/10.1016/j.pbi.2013.04.001
[9] Mashego, M.R., Rumbold, K., De Mey, M., et al. (2007) Micro-bial Metabolomics: Past, Present and Future Methodologies. Biotechnology Letters, 29, 1-16.
http://dx.doi.org/10.1007/s10529-006-9218-0
[10] Nambiar, P.R., Gupta, R.R. and Misra, V. (2010) An “Omics” Based Survey of Human Colon Cancer. Mutation Research, 693, 3-18.
http://dx.doi.org/10.1016/j.mrfmmm.2010.07.008
[11] Fiehn, O. (2002) Metabolomics—The Link between Gen-otypes and Phenotypes. Plant Molecular Biology, 48, 155-171.
http://dx.doi.org/10.1023/A:1013713905833
[12] Oliver, S.G., Winson, M.K., Kell, D.B., et al. (1998) Systematic Functional Analysis of the Yeast Genome. Trends in Biotechnology, 16, 373-378.
http://dx.doi.org/10.1016/S0167-7799(98)01214-1
[13] Nicholson, J.K., Lindon, J.C. and Holmes, E. (1999) “Metabonomics”: Understanding the Metabolic Responses of Living Systems to Pathophysiological Stimuli via Multi-variate Statistical Analysis of Biological NMR Spectroscopic Data. Xenobiotica, 29, 1181-1189.
http://dx.doi.org/10.1080/004982599238047
[14] Fiehn, O., Kopka, J., Dormann, P., et al. (2000) Metabolite Profiling for Plant Functional Genomics. Nature Biotechnology, 18, 1157-1161.
http://dx.doi.org/10.1038/81137
[15] Wishart, D.S., Jewison, T., Guo, A.C., et al. (2013) HMDB 3.0—The Hu-man Metabolome Database in 2013. Nucleic Acids Research, 41, D801-D807.
http://dx.doi.org/10.1093/nar/gks1065
[16] Mal, M., Koh, P.K., Cheah, P.Y. and Chan, E.C.Y. (2012) Metabo-typing of Human Colorectal Cancer Using Two- Dimensional Gas Chromatography Mass Spectrometry. Analytical and Bioanalytical Chemistry, 403, 483-493.
http://dx.doi.org/10.1007/s00216-012-5870-5
[17] Dettmer, K. and Hammock, B.D. (2004) Metabolomics—A New Exciting Field within the “Omics” Sciences. Environmental Health Perspectives, 112, A396-A397.
[18] Patti, G.J., Yanes, O. and Siuzdak, G. (2012) Innovation: Metabolomics: The Apogee of the Omics Trilogy. Nature Reviews Molecular Cell Biology, 13, 263-269.
http://dx.doi.org/10.1038/nrm3314
[19] Griffin, J.L. and Shockcor, J.P. (2004) Metabolic Profiles of Cancer Cells. Nature Reviews Cancer, 4, 551-561.
http://dx.doi.org/10.1038/nrc1390
[20] Tang, B., Hsu, P.Y., Huang, T.H. and Jin, V.X. (2013) Cancer Omics: From Regulatory Networks to Clinical Outcomes. Cancer Letters, 340, 277-283.
http://dx.doi.org/10.1016/j.canlet.2012.11.033
[21] Stratton, M.R., Campbell, P.J. and Futreal, P.A. (2009) The Cancer Genome. Nature, 458, 719-724.
http://dx.doi.org/10.1038/nature07943
[22] Hanash, S. and Taguchi, A. (2010) The Grand Challenge to Decipher the Cancer Proteome. Nature Reviews Cancer, 10, 652-660.
http://dx.doi.org/10.1038/nrc2918
[23] Hewitson, P., Glasziou, P., Watson, E., Towler, B. and Irwig, L. (2008) Cochrane Systematic Review of Colorectal Cancer Screening Using the Fecal Occult Blood Test (Hemoccult): An Update. The American Journal of Gastroenterology, 103, 1541-1549.
http://dx.doi.org/10.1111/j.1572-0241.2008.01875.x
[24] Bandi, P., Cokkinides, V., Smith, R.A. and Jemal, A. (2012) Trends in Colorectal Cancer Screening with Home-Based Fecal Occult Blood Tests in Adults Ages 50 to 64 Years, 2000-2008. Cancer, 118, 5092-5099.
[25] van Rossum, L.G., van Rijn, A.F., Laheij, R.J., et al. (2008) Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population. Gastroenterology, 135, 82-90.
http://dx.doi.org/10.1053/j.gastro.2008.03.040
[26] Selby, J.V., Friedman, G.D., Quesenberry, C.J. and Weiss, N.S. (1992) A Case-Control Study of Screening Sigmoidoscopy and Mortality from Colorectal Cancer. The New Eng-land Journal of Medicine, 326, 653-657.
http://dx.doi.org/10.1056/NEJM199203053261001
[27] Lieberman, D.A., Harford, W.V., Ahnen, D.J., et al. (2001) One-Time Screening for Colorectal Cancer with Combined Fecal Occult-Blood Testing and Examination of the Distal Colon. The New England Journal of Medicine, 345, 555-560.
http://dx.doi.org/10.1056/NEJMoa010328
[28] Zauber, A.G., Winawer, S.J., O’Brien, M.J., et al. (2012) Colon-oscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths. The New England Journal of Medicine, 366, 687-696.
http://dx.doi.org/10.1056/NEJMoa1100370
[29] Ganeshan, D., Elsayes, K.M. and Vining, D. (2013) Virtual Co-lonoscopy: Utility, Impact and Overview. World Journal of Radiology, 28, 61-67.
http://dx.doi.org/10.4329/wjr.v5.i3.61
[30] Fenlon, H.M., Nunes, D.P., Schroy, P.C., Barish, M.A., Clarke, P.D. and Ferrucci, J.T. (1999) A Comparison of Virtual and Conventional Colonoscopy for the Detection of Colorectal Polyps. The New England Journal of Medicine, 341, 1496-1503.
http://dx.doi.org/10.1056/NEJM199911113412003
[31] Ikeda, A., Nishiumi, S., Shinohara, M., et al. (2012) Se-rum Metabolomics as a Novel Diagnostic Approach for Gastrointestinal Cancer. Biomedical Chromatography, 26, 548-558.
http://dx.doi.org/10.1002/bmc.1671
[32] Nishiumi, S., Kobayashi, T., Ikeda, A., et al. (2012) A Novel Serum Metabolomics-Based Diagnostic Approach for Colorectal Cancer. PLoS ONE, 7, e40459.
http://dx.doi.org/10.1371/journal.pone.0040459
[33] Ritchie, S.A., Ahiahonu, P.W., Jayasinghe, D., et al. (2010) Reduced Levels of Hydroxylated, Polyunsaturated Ultra Long-Chain Fatty Acids in the Serum of Colorectal Cancer Patients: Implications for Early Screening and Detection. BMC Medicine, 8, 13.
http://dx.doi.org/10.1186/1741-7015-8-13
[34] Chen, C., Deng, L.L., Wei, S.W., et al. (2015) Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression. Journal of Proteome Research, 14, 2492-2499.
http://dx.doi.org/10.1021/acs.jproteome.5b00059
[35] Patel, K. (2010) Noninvasive Tools to Assess Liver Disease. Current Opinion in Gastroenterology, 26, 227-233.
http://dx.doi.org/10.1097/MOG.0b013e3283383c68
[36] Kneepkens, C.M., Lepage, G. and Roy, C.C. (1994) The Potential of the Hydrocarbon Breath Test as a Measure of Lipid Peroxidation. Free Radical Biology and Medicine, 17, 127-160.
http://dx.doi.org/10.1016/0891-5849(94)90110-4
[37] Toyokuni, S. (2008) Molecular Mechanisms of Oxidative Stress-Induced Carcinogenesis: From Epidemiology to Oxygenomics. IUBMB Life, 60, 441-447.
http://dx.doi.org/10.1002/iub.61
[38] Altomare, D.F., Di Lena, M., Porcelli, F., et al. (2013) Author’s Reply: Ex-haled Volatile Organic Compounds Identify Patients with Colorectal Cancer. British Journal of Surgery, 100, 144-150.
http://dx.doi.org/10.1002/bjs.8942
[39] Silva, C.L., Passos, M. and Camara, J.S. (2011) Investigation of Urinary Volatile Organic Metabolites as Potential Cancer Biomarkers by Solid-Phase Microextraction in Combination with Gas Chromatography-Mass Spectrometry. British Journal of Cancer, 105, 1894-1904.
http://dx.doi.org/10.1038/bjc.2011.437
[40] Cheng, Y., Xie, G.X., Chen, T.L., et al. (2012) Distinct Urinary Metabolic Profile of Human Colorectal Cancer. Journal of Proteome Research, 11, 1354-1363.
http://dx.doi.org/10.1021/pr201001a
[41] Monleon, D., Morales, J.M., Barrasa, A., López, J.A., Vázquez, C. and Celda, B. (2009) Metabolite Profiling of Fecal Water Extracts from Human Colorectal Cancer. NMR in Biomedicine, 22, 342-348.
http://dx.doi.org/10.1002/nbm.1345
[42] Ma, Y.L., Zhang, P., Wang, F., Liu, W.J., Yang, J.J. and Qin, H.L. (2012) An Integrated Proteomics and Metabolomics Approach for Defining Oncofetal Biomarkers in the Colorectal Cancer. Annals of Surgery, 255, 720-730.
http://dx.doi.org/10.1097/SLA.0b013e31824a9a8b
[43] Ong, E.S., Zou, L., Li, S.X., Cheah, P.Y., Eu, K.W. and Ong, C.N. (2010) Metabolic Profiling in Colorectal Cancer Reveals Signature Metabolic Shifts during Tumorigenesis. Molecular & Cellular Proteomics.
http://dx.doi.org/10.1074/mcp.M900551-MCP200
[44] Williams, M.D., Zhang, X., Belton, A.S., et al. (2015) HMGA1 Drives Metabolic Reprogramming of Intestinal Epithelium during Hyperproliferation, Polyposis, and Colorectal Carcinogenesis. Journal of Proteome Research, 14, 1420- 1431.
http://dx.doi.org/10.1021/pr501084s